Literature DB >> 16801534

STAT3: a multifaceted oncogene.

David E Levy1, Giorgio Inghirami2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801534      PMCID： PMC1502425          DOI： 10.1073/pnas.0604042103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  14 in total

Review 1.  Stats: transcriptional control and biological impact.

Authors:  David E Levy; J E Darnell
Journal:  Nat Rev Mol Cell Biol       Date:  2002-09       Impact factor: 94.444

Review 2.  Regulatory T cells and mechanisms of immune system control.

Authors:  Anne O'Garra; Paulo Vieira
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

3.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

4.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Authors:  Monika Kasprzycka; Michal Marzec; Xiaobin Liu; Qian Zhang; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

5.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

Review 6.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.

Authors:  C L Yu; D J Meyer; G S Campbell; A C Larner; C Carter-Su; J Schwartz; R Jove
Journal:  Science       Date:  1995-07-07       Impact factor: 47.728

Review 8.  Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

Authors:  Ana M Gamero; Howard A Young; Robert H Wiltrout
Journal:  Cancer Cell       Date:  2004-02       Impact factor: 31.743

9.  Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.

Authors:  Hesham M Amin; Timothy J McDonnell; Yupo Ma; Quan Lin; Yasushi Fujio; Keita Kunisada; Vasiliki Leventaki; Pamela Das; George Z Rassidakis; Cathy Cutler; L Jeffrey Medeiros; Raymond Lai
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

Review 10.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745
View more
  45 in total

1.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

2.  Constitutive activation of STAT3 and cyclin D1 overexpression contribute to proliferation, migration and invasion in gastric cancer cells.

Authors:  Jianfei Luo; Ruicheng Yan; Xiaobo He; Jie He
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

3.  Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity.

Authors:  Tiancen Hu; Jennifer E Yeh; Luca Pinello; Jaison Jacob; Srinivas Chakravarthy; Guo-Cheng Yuan; Rajiv Chopra; David A Frank
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

Review 4.  Peptide carriers to the rescue: overcoming the barriers to siRNA delivery for cancer treatment.

Authors:  James C Cummings; Haiwen Zhang; Andrew Jakymiw
Journal:  Transl Res       Date:  2019-07-29       Impact factor: 7.012

5.  SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage.

Authors:  Seong Won Lee; Moon Hee Lee; Jong Ho Park; Sung Hwan Kang; Hee Min Yoo; Seung Hyun Ka; Young Mi Oh; Young Joo Jeon; Chin Ha Chung
Journal:  EMBO J       Date:  2012-10-23       Impact factor: 11.598

6.  Regulation of human endometrial stromal proliferation and differentiation by C/EBPβ involves cyclin E-cdk2 and STAT3.

Authors:  Wei Wang; Robert N Taylor; Indrani C Bagchi; Milan K Bagchi
Journal:  Mol Endocrinol       Date:  2012-10-24

Review 7.  Never say die: survival signaling in large granular lymphocyte leukemia.

Authors:  Mithun Vinod Shah; Ranran Zhang; Thomas P Loughran
Journal:  Clin Lymphoma Myeloma       Date:  2009

8.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

9.  Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

Authors:  Coralie Hoareau-Aveilla; Thibaud Valentin; Camille Daugrois; Cathy Quelen; Géraldine Mitou; Samuel Quentin; Jinsong Jia; Salvatore Spicuglia; Pierre Ferrier; Monica Ceccon; Sylvie Giuriato; Carlo Gambacorti-Passerini; Pierre Brousset; Laurence Lamant; Fabienne Meggetto
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

Review 10.  Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.

Authors:  Matthew R Pawlus; Cheng-Jun Hu
Journal:  Cell Signal       Date:  2013-05-21       Impact factor: 4.315
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.